ArticleNature communications2025
Phosphorylation of PA28γ by CK2 kinase facilitates HNSCC tumor formation and progression.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Proteasome activator 28 subunit gamma (PA28γ) attracts considerable attention for its ability to regulate multiple molecules involved in tumor progression. However, its intrinsic activation and functional regulatory mechanisms in the regulation of tumor growth remain incompletely understood. Here, using head and neck squamous cell carcinoma (HNSCC) as a model, we identify phosphorylation at the T23 site of PA28γ, a modification that is highly expressed across pan-cancer types and associated with poor prognosis. Notably, phosphorylation-deficient PA28γ-T23 mutant mice exhibit resistance to carcinogen-induced HNSCC tumors, whereas the phosphomimetic PA28γ-T23 mutant promotes tumor formation and progression. We subsequently explore the underlying mechanism and find that casein kinase 2 (CK2) mediates PA28γ-T23 phosphorylation, which regulates the abundance of growth-related E4F transcription factor 1 (E4F1) through the PA28γ-proteasome pathway. These findings highlight PA28γ-T23 phosphorylation as a crucial pro-oncogenic signal and an unfavorable prognostic indicator across various cancers and underscore its potential as a target for early cancer intervention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.